Literature DB >> 26077248

Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections.

Silvia Gómez-Zorrilla1, Mariana Camoez2, Fe Tubau2, Rosario Cañizares3, Elisabet Periche3, M Angeles Dominguez2, Javier Ariza1, Carmen Peña4.   

Abstract

The potential role of Pseudomonas aeruginosa (PA) intestinal colonization in the subsequent development of infections has not been thoroughly investigated. The aims of this study were to assess the role of PA intestinal colonization as a predictor of subsequent infections and to investigate the risk factors associated with the development of PA infection in patients in the intensive care unit (ICU). For this purpose, a prospective study was conducted that included (i) active surveillance of PA rectal colonization at ICU admission and weekly until ICU discharge, (ii) detection of PA clinical infections, and (iii) genotypic analysis by pulsed-field gel electrophoresis (PFGE). A total of 414 patients were included, of whom 179 (43%) were colonized with PA. Among the 77 patients who developed PA infection, 69 (90%) had prior PA colonization, and 60 (87%) of these showed genotyping concordance between rectal and clinical isolates. The probability of PA infection 14 days after ICU admission was 26% for carriers versus 5% for noncarriers (P < 0.001). Cox regression analysis identified prior PA rectal colonization as the main predictor of PA infection (hazard ratio [HR], 15.23; 95% confidence interval [CI], 6.9 to 33.7; P < 0.001). Prior use of nonantipseudomonal penicillins was also identified as an independent variable associated with PA infection (HR, 2.15; 95% CI, 1.3 to 3.55; P < 0.003). Our study demonstrated that prior PA rectal colonization is a key factor for developing PA infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26077248      PMCID: PMC4538513          DOI: 10.1128/AAC.04636-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

2.  Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit.

Authors:  Stijn Blot; Pieter Depuydt; Dirk Vogelaers; Johan Decruyenaere; Jan De Waele; Eric Hoste; Renaat Peleman; Geert Claeys; Gerda Verschraegen; Francis Colardyn; Koenraad Vandewoude
Journal:  Infect Control Hosp Epidemiol       Date:  2005-06       Impact factor: 3.254

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  A simplified acute physiology score for ICU patients.

Authors:  J R Le Gall; P Loirat; A Alperovitch; P Glaser; C Granthil; D Mathieu; P Mercier; R Thomas; D Villers
Journal:  Crit Care Med       Date:  1984-11       Impact factor: 7.598

5.  Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units.

Authors:  X Bertrand; M Thouverez; D Talon; A Boillot; G Capellier; C Floriot; J P Hélias
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

6.  Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract.

Authors:  Tomoko Ohara; Kouichi Itoh
Journal:  Intern Med       Date:  2003-11       Impact factor: 1.271

7.  Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.

Authors:  Elisabeth Kugelberg; Sonja Löfmark; Bengt Wretlind; Dan I Andersson
Journal:  J Antimicrob Chemother       Date:  2004-12-01       Impact factor: 5.790

8.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study.

Authors:  E J Giamarellos-Bourboulis; D Plachouras; A Tzivra; V Kousoulas; N Bolanos; M Raftogiannis; I Galani; I Dontas; A Dionyssiou-Asteriou; H Giamarellou
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

10.  Pseudomonas aeruginosa colonisation in an intensive therapy unit: role of cross infection and host factors.

Authors:  M R Noone; T L Pitt; M Bedder; A M Hewlett; K B Rogers
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29
View more
  19 in total

1.  Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.

Authors:  Christopher R Frei; Sylvie Rehani; Grace C Lee; Natalie K Boyd; Erene Attia; Ashley Pechal; Rachel S Britt; Eric M Mortensen
Journal:  Pharmacotherapy       Date:  2017-02-03       Impact factor: 4.705

2.  Long-Term Dominance of Carbapenem-Non-Susceptible Pseudomonas aeruginosa ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients.

Authors:  Liyang Zhang; Filemon C Tan; Lynne Strasfeld; Morgan Hakki; Natalia V Kirienko
Journal:  Front Cell Infect Microbiol       Date:  2022-06-16       Impact factor: 6.073

3.  Existence of Multiple ESBL Genes among Phenotypically Confirmed ESBL Producing Klebsiella pneumoniae and Escherichia coli Concurrently Isolated from Clinical, Colonization and Contamination Samples from Neonatal Units at Bugando Medical Center, Mwanza, Tanzania.

Authors:  Vitus Silago; Dory Kovacs; Happyness Samson; Jeremiah Seni; Louise Matthews; Katarina Oravcová; Athumani M Lupindu; Abubakar S Hoza; Stephen E Mshana
Journal:  Antibiotics (Basel)       Date:  2021-04-21

4.  Acute ileitis facilitates infection with multidrug resistant Pseudomonas aeruginosa in human microbiota-associated mice.

Authors:  Eliane von Klitzing; Ira Ekmekciu; Stefan Bereswill; Markus M Heimesaat
Journal:  Gut Pathog       Date:  2017-01-18       Impact factor: 4.181

5.  A prospective survey of Pseudomonas aeruginosa colonization and infection in the intensive care unit.

Authors:  Regev Cohen; Frida Babushkin; Shoshana Cohen; Marina Afraimov; Maurice Shapiro; Martina Uda; Efrat Khabra; Amos Adler; Ronen Ben Ami; Svetlana Paikin
Journal:  Antimicrob Resist Infect Control       Date:  2017-01-11       Impact factor: 4.887

6.  Intestinal and Systemic Immune Responses upon Multi-drug Resistant Pseudomonas aeruginosa Colonization of Mice Harboring a Human Gut Microbiota.

Authors:  Eliane von Klitzing; Ira Ekmekciu; Stefan Bereswill; Markus M Heimesaat
Journal:  Front Microbiol       Date:  2017-12-22       Impact factor: 5.640

7.  Risk factors for colonization and infection by Pseudomonas aeruginosa in patients hospitalized in intensive care units in France.

Authors:  S Hoang; A Georget; J Asselineau; A-G Venier; C Leroyer; A M Rogues; R Thiébaut
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

8.  Multidrug-resistant Pseudomonas aeruginosa aggravates inflammatory responses in murine chronic colitis.

Authors:  Eliane von Klitzing; Ira Ekmekciu; Anja A Kühl; Stefan Bereswill; Markus M Heimesaat
Journal:  Sci Rep       Date:  2018-04-27       Impact factor: 4.379

9.  Multidrug-Resistant Pseudomonas Aeruginosa Induce Systemic Pro-Inflammatory Immune Responses in Colonized Mice.

Authors:  Eliane von Klitzing; Stefan Bereswill; Markus M Heimesaat
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-09-11

10.  Toll-like receptor-4 differentially mediates intestinal and extra-intestinal immune responses upon multi-drug resistant Pseudomonas aeruginosa association of IL10-/- mice with chronic colitis.

Authors:  Anne Grunau; Ulrike Escher; Anja A Kühl; Stefan Bereswill; Markus M Heimesaat
Journal:  Gut Pathog       Date:  2017-11-07       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.